|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Obesity | |||||
| Dyslipidemia | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Dyslipidemias | |||||
| 3 | More general conditions related to this trial | ||||
| Body Weight | |||||
| Lipid Metabolism Disorders | |||||
| Metabolic Diseases | |||||
| Nutrition Disorders | |||||
| Overnutrition | |||||
| Overweight | |||||
| Signs and Symptoms | |||||
| 4 | Interventions listed in this trial | ||||
| Rimonabant (SR141716) | |||||
| 5 | Sponsors listed in this trial | ||||
| Sanofi-Aventis | |||||